Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response
Y Sato, Y Fu, H Liu, MY Lee, MH Shaw - BMC cancer, 2021 - Springer
Background Immune checkpoint blockade (ICB) therapies have changed the paradigm of
cancer therapies. However, anti-tumor response of the ICB is insufficient for many patients …
cancer therapies. However, anti-tumor response of the ICB is insufficient for many patients …
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade
D Ajona, S Ortiz-Espinosa, T Lozano, F Exposito… - Nature Cancer, 2020 - nature.com
Harnessing the immune system by blocking the programmed cell death protein 1 (PD-1)
pathway has been a major breakthrough in non-small-cell lung cancer treatment …
pathway has been a major breakthrough in non-small-cell lung cancer treatment …
Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy
N Principe, J Kidman, S Goh, CM Tilsed… - Frontiers in …, 2020 - frontiersin.org
Immune checkpoint therapy (ICT) results in durable responses in individuals with some
cancers, but not all patients respond to treatment. ICT improves CD8+ cytotoxic T …
cancers, but not all patients respond to treatment. ICT improves CD8+ cytotoxic T …
Regulatory T-cells as an emerging barrier to immune checkpoint inhibition in lung cancer
DR Principe, L Chiec, NA Mohindra… - Frontiers in oncology, 2021 - frontiersin.org
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm for lung
cancer in recent years. These strategies consist of neutralizing antibodies against negative …
cancer in recent years. These strategies consist of neutralizing antibodies against negative …
Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors
DS Thommen, J Schreiner, P Müller, P Herzig… - Cancer immunology …, 2015 - AACR
Dysfunctional T cells present in malignant lesions are characterized by a sustained and
highly diverse expression of inhibitory receptors, also referred to as immune checkpoints …
highly diverse expression of inhibitory receptors, also referred to as immune checkpoints …
Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go
A Vasaturo, S Di Blasio, DGA Peeters… - Frontiers in …, 2013 - frontiersin.org
The aim of therapeutic dendritic cell (DC) vaccines in cancer immunotherapy is to activate
cytotoxic T cells to recognize and attack the tumor. T cell activation requires the interaction of …
cytotoxic T cells to recognize and attack the tumor. T cell activation requires the interaction of …
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
Cancer immunotherapy using antibodies that target immune checkpoints has delivered
outstanding results. However, responses only occur in a subset of patients, and it is not fully …
outstanding results. However, responses only occur in a subset of patients, and it is not fully …
CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
A Kunert, EA Basak, DP Hurkmans… - … for immunotherapy of …, 2019 - Springer
Background Checkpoint inhibitors have become standard care of treatment for non-small
cell lung cancer (NSCLC), yet only a limited fraction of patients experiences durable clinical …
cell lung cancer (NSCLC), yet only a limited fraction of patients experiences durable clinical …
[HTML][HTML] Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion
CD47 on tumor cells protects from phagocytosis, while PD-L1 dampens T cell-mediated
tumor killing. However, whether and how CD47 and PD-L1 coordinate is poorly understood …
tumor killing. However, whether and how CD47 and PD-L1 coordinate is poorly understood …
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)–
programmed cell death ligand-1 (PD-L1) axis have shown promising results in non-small …
programmed cell death ligand-1 (PD-L1) axis have shown promising results in non-small …